Tumor growth and angiogenesis is impaired in CIB1 knockout mice by Parise, Leslie et al.
RESEARCH Open Access
Tumor growth and angiogenesis is impaired in
CIB1 knockout mice
Mohamed A Zayed1,4, Weiping Yuan2,5, Dan Chalothorn3, James E Faber3, Leslie V Parise1,2*
Abstract
Background: Pathological angiogenesis contributes to various ocular, malignant, and inflammatory disorders,
emphasizing the need to understand this process more precisely on a molecular level. Previously we found that
CIB1, a 22 kDa regulatory protein, plays a critical role in endothelial cell function, angiogenic growth factor-
mediated cellular functions, PAK1 activation, MMP-2 expression, and in vivo ischemia-induced angiogenesis. Since
pathological angiogenesis is highly dependent on many of these same processes, we hypothesized that CIB1 may
also regulate tumor-induced angiogenesis.
Methods: To test this hypothesis, we allografted either murine B16 melanoma or Lewis lung carcinoma cells into
WT and CIB1-KO mice, and monitored tumor growth, morphology, histology, and intra-tumoral microvessel density.
Results: Allografted melanoma tumors that developed in CIB1-KO mice were smaller in volume, had a distinct
necrotic appearance, and had significantly less intra-tumoral microvessel density. Similarly, allografted Lewis lung
carcinoma tumors in CIB1-KO mice were smaller in volume and mass, and appeared to have decreased perfusion.
Intra-tumoral hemorrhage, necrosis, and perivascular fibrosis were also increased in tumors that developed in CIB1-
KO mice.
Conclusions: These findings suggest that, in addition to its other functions, CIB1 plays a critical role in facilitating
tumor growth and tumor-induced angiogenesis.
Background
Pathological angiogenesis is a hallmark of tumorigenesis
and is a discrete event in solid tumor formation [1,2].
Unlike physiological forms of angiogenesis that occur
during embryonic development and normal wound heal-
ing, pathological, tumor-induced angiogenesis often
ensues due to imbalances in either angiogenic activators
or inhibitors [1,3]. Recent pre-clinical and clinical stu-
dies have employed strategies to target tumor vascula-
ture as a means to impede tumor growth and eventual
metastasis [4,5]. However, thus far monotherapy with
such agents in human subjects has been limited due to
marginal effectiveness, toxicities, and relative lack of
specificity [6,7]. Therefore, further exploration is cur-
rently underway for more specific drug targets that are
not essential for physiological forms of angiogenesis.
CIB1 is a 22 kDa EF-hand-containing regulatory pro-
tein that was originally identified as a binding partner
for the cytoplasmic tail of the platelet integrin aIIb, and
later found to inhibit aIIbb3 activation in megakaryo-
cytes [8,9]. Subsequently however, CIB1 was found to be
widely expressed in various organs, tissues, and cell
types, which suggested that it likely has additional
uncharacterized roles [10,11]. Accordingly, we and
others have demonstrated that CIB1 binds to and regu-
lates the activity of various proteins including the tran-
scription factor PAX3 [12], the polo-like kinase Fnk and
Snk [13], the inositol 1,4,5-triphosphate receptor [14],
Rac3 [15], PAK1 [16], and FAK [17]. Among these bind-
ing partners, PAK1 and FAK are known to regulate
endothelial cell (EC) function in vitro, and contribute to
angiogenesis in vivo [18-20]. Therefore, this connection
led us to investigate whether CIB1 can also play a role
in EC function and various forms of angiogenesis.
Recently, we reported that CIB1 is not required for
developmental angiogenesis, as CIB1-KO mice are viable
and female mice are fertile [9]. However, CIB1 is
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essential for proper EC signaling and functions such as
migration, proliferation, and nascent tubule formation
[21]. Loss of CIB1 in ECs also leads to attenuated
responses to angiogenic growth factors such as VEGF
and FGF-2, which result in decreased expression of the
zinc-requiring matrix-degrading proteinase MMP-2.
Moreover, CIB1-KO mice are impaired in pathological
as well as adaptive forms of ischemia-induced angiogen-
esis, and PAK1 and ERK1/2 activation are significantly
decreased in CIB1-KO ECs and ischemic muscle tissue
[21]. Although these data clearly demonstrate that CIB1
participates in ischemia-induced angiogenesis in vivo, its
role in other forms of pathological angiogenesis, like
tumor-induced angiogenesis is still unclear.
As in ischemia-induced angiogenesis, tumor-induced
angiogenesis is highly dependent on angiogenic growth
factors and MMPs [22-24]. Accordingly, tumor allo-
grafts in knockout mice for growth factors such as
FGF-2 and MMPs such as MMP-2 and MMP-9 exhibit
significantly reduced tumor growth and tumor-induced
angiogenesis [1,25,26]. Since our previous studies
demonstrated that CIB1-KO mice have decreased
growth factor-mediated angiogenesis, and CIB1-KO
ECs have attenuated MMP-2 expression, we hypothe-
sized that CIB1-KO mice may also have a defect in
tumor-induced angiogenesis. To test this conjecture we
allografted CIB1-KO mice with murine tumor cells
that endogenously expressed either very low levels
(B16 melanoma tumor cells) or very high levels (Lewis
lung carcinoma cells) of MMP-2, as previously demon-
strated by zymography analysis [25]. We report here
that, in addition to regulating tumor growth, CIB1 in
the host significantly contributes to tumor-induced
angiogenesis.
Methods
Allografts
Male WT and CIB1-KO mice between 15 and 18 weeks
old were anesthetized with 1.125% isoflurane supple-
mented with 2:3 oxygen-air. Rectal temperature was clo-
sely maintained at 37.0 ± 0.5°C. Hair was removed from
the hind-limb ventral adductor thigh region using depi-
lating cream, with care to avoid erythema. Mice were
given a single subcutaneous injection of either 5 × 105
B16 melanoma cells (purchased from UNC-CH Tissue
Culture Facility) or 2.5 × 105 Lewis lung carcinoma cells
(ATCC, Manassas, VA) that were impregnated in 50 μL
of 50% growth factor reduced Matrigel. Tumor allografts
were grossly inspected 14 days after tumor cell injec-
tions, and photographs were obtained to document
differences in tumor morphology between WT and
CIB1-KO mice (n = 8-11 mice per group). Gross tumor
necrosis was defined by superficial discoloration of the
tumor. Fourteen days after tumor cell injection, tumors
were isolated from animals, and were weighed and then
immersed in water to estimate the tumor volume.
Tumor fixation, histology, and capillary density
assessment
Tumors isolated from animals were fixed in 2% PFA for
48 h, with a solution change at 24 h. Tumors were
rinsed in water, placed in 70% ethanol for 48 h with
shaking and another change of solution at 24 h. Four
biopsies (~2-3 mm in size) were obtained from both the
center and periphery of each tumor and embedded in
paraffin. At least 3 interrupted sections, 6 μm thick and
50 μm apart, were obtained and stained with either
H&E, or Masson’s trichrome (MT), a marker for fibro-
sis-associated collagen deposition[27]. For each tumor,
one random interrupted section of all four biopsies was
assessed for the incidence of necrosis or intra-tumoral
bleeding, spanning 70% of the biopsy tissue section.
Similarly, one random interrupted section of each biopsy
was assessed for the incidence of perivascular fibrosis.
To assess capillary density, the plasma membranes of
capillary ECs in tumor sections were labeled with Alexa
Fluor 594-conjugated isolectin GSL-1-B4 (1:100; Invitro-
gen), or with primary rat anti-mouse CD31 (PECAM-1)
antibody (1:50; Pharmingen) and subsequently Alexa
Fluor 594-conjugated secondary goat anti-rat IgG
(1:1000; Invitrogen). Using a Nikon TE2000U inverted
fluorescent microscope with an OrcaER, four high mag-
nification immunoflorescent and H&E images were col-
lected for each biopsy to yield a total of 16 images per
tumor specimen. Using ImageJ software, the number of
vessels with a clear lumen and < 7 μm were counted by
an independent observer, who was blinded as to animal
genotypes. Tumor microvessel density was reported as
the average number of microvessels per high-magnifica-
tion frame.
Statistical Analysis
Continuous variables were compared with the Student’s
t test. We considered P < 0.05 to be significant.
Results and Discussion
Almost all tumor cells secret angiogenic growth factors
and MMPs (such as MMP-2 and MMP-9) to recruit
and stimulate new blood vessel formation [1,28]. Since
we reported previously that CIB1-KO mouse tissue and
ECs have reduced growth factor-induced angiogenesis
and MMP-2 expression [21], we asked whether CIB1-
KO mice also have a defect in tumor-induced angiogen-
esis. To address this question we subcutaneously
injected the adductor hindlimb regions of WT and
CIB1-KO mice with B16 melanoma tumor cells (which
are known to secrete angiogenic growth factors such as
VEGF, FGF-2, PDGF, but only very low levels of
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gelatinases MMP-2 and MMP-9), and Lewis lung carci-
noma tumor cells (which, in addition to secreting var-
ious angiogenic growth factors, secrete higher levels of
MMP-2 and MMP-9) [29].
Fourteen days after tumor cell injection, signs of mela-
noma tumor necrosis were evident in a large subset of
CIB1-KO mice (Figure 1a). Tumors in approximately
64% of CIB1-KO mice demonstrated evidence of gross
morphological necrosis compared to 33% of WT mice
(Table 1). This observation prompted us to immediately
terminate the study and harvest allografted tumors from
WT and CIB1-KO mice for further analysis. Gross dis-
section of melanoma tumors from CIB1-KO mice
revealed that a large subset of these tumors were com-
posed of highly necrotic fluid-laden tissue, and sur-
rounded by small pockets of bleeding. In contrast,
melanoma tumors extracted from WT mice were more
homogenous and dense, and surrounded by less areas of
bleeding. Furthermore, melanomas extracted from
CIB1-KO mice were significantly reduced in volume
(32% decrease, p = 0.05), but not weight (8% decrease,
p = 0.34; Figure 1b and 1c). The decreased volume and
increased gross necrosis of melanoma tumors in CIB1-
KO mice suggest that these tumors were not as well
sustained metabolically and therefore were not growing
as rapidly as melanomas in WT mice. In part, this dif-
ference may be explained by the relative lack of MMP-2
in the tumor and peri-tumor micro-environment in
CIB1-KO mice, leading to reduced tumor angiogenesis,
thus mimicking the reported phenotype of reduced allo-
graft tumor growth and angiogenesis in MMP-2-KO
mice [25].
Interestingly, unlike the allografted melanoma tumors,
none of the Lewis lung carcinoma tumors that devel-
oped in CIB1-KO and WT mice demonstrated evidence
of gross morphological necrosis (Table 1 and Figure 1a).
Compared to melanoma tumors, the complete lack of
gross necrosis in carcinoma tumor in CIB1-KO mice
may be due to differences in the physiology and cellular
metabolic demand of Lewis lung carcinoma cells. Alter-
natively, this difference may be attributed to the ability
of Lewis lung carcinoma cells to express and secrete
high levels of MMP-2, which does not occur as effec-
tively in B16 melanoma cells. Nevertheless, similar to
melanoma tumors in CIB1-KO mice, Lewis lung carci-
nomas were also 30% reduced in weight and 35%
reduced in volume when compared to these carcinomas
in WT mice (p = 0.02 and 0.008, respectively; Figure 1b
and 1c).
Moreover, carcinomas in CIB1-KO mice also appeared
more blanched (Figure 1a), which suggested that these
tumors were not as well perfused. To measure perfusion
in Lewis Lung carcinoma tumors we used a non-inva-
sive Doppler flowmeter for periodic assessment of
tumor perfusion in real-time. Doppler perfusion of mel-
anoma tumors in CIB1-KO mice was not assessed since
they appeared to be grossly necrotic in appearance.
Doppler images of 14 day old carcinomas demonstrated
areas of clearly higher tumor perfusion in WT, but not
CIB1-KO mice (areas in white; Additional file 1: Figure
1a). Quantification of these data also demonstrated a
trend of reduced carcinoma tumor perfusion in CIB1-
KO mice. However, due to variations in tumor dimen-
sions and orientation, no overall statistically significant
differences were extrapolated from this analysis (Addi-
tional file 1: Figure 1b). Nevertheless, like melanoma
allografts, the decreased size and differences in carci-
noma allograft gross appearance in CIB1-KO mice sug-
gest that these tumors were not growing as efficiently as
carcinomas in WT mice.
To further assess the allograft melanoma and carci-
noma micro-environments we obtained biopsies from
allograft tumor peripheries and centers. To minimize
sample bias, biopsies were obtained from random loca-
tions and we histologically examined random areas of
each biopsy section. Histological examination at low and
high magnification of melanoma biopsies from WT and
CIB1-KO mice revealed areas of tumor necrosis and
intra-tumoral bleeding. However, melanoma biopsies
from CIB1-KO mice contained larger areas of tumor
necrosis and intra-tumoral bleeding (Figure 2a, b, d, and
2e). Similarly, intra-tumoral and perivascular fibrosis,
associated with tissue injury and fibrosis, was more fre-
quently found in melanoma tumors in CIB1-KO mice
(Figure 2c and 2f). Although these differences in peri-
vascular fibrosis, and intra-tumoral necrosis and bleed-
ing (that span at least 70% of a biopsy’s surface area)
were not statistically significant in melanoma tumors,
the incidences were higher in CIB1-KO mice compared
to WT mice (p = 0.37, and 0.11 respectively; data not
shown). Similar examination of carcinoma tumor biop-
sies from CIB1-KO and WT mice also revealed distinct
areas of intra-tumoral necrosis and bleeding; however
differences in the overall incidence of this between
CIB1-KO and WT mice were less pronounced com-
pared to those noted for melanoma tumors (Figure 2g,
h, j, and 2k). Minimal perivascular fibrosis was observed
in carcinoma tumors in both WT and CIB1-KO mice
(Figure 2i and 2l). These histological observations are
consistent with our gross observations, and therefore
further suggest that in an MMP-2-deficient micro-envir-
onment in CIB1-KO mice, melanoma tumors are less
viable and have significantly impaired growth.
Reduced tumor size and increased tumor necrosis
observed in CIB1-KO allografts may also be due to
reduced tumor-induced angiogenesis that is necessary
for efficient delivery of oxygen and essential nutrients to
the proliferating tumor cells. Thus, we assessed the
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microvessel density in sections obtained from biopsies of
melanoma and carcinoma allografts that developed in
both CIB1-KO and WT mice with either PECAM-1 or
Isolectin GSL1-B4. Isolectin GSL1-B4-stained microves-
sels were noted in melanoma tumor sections, and simi-
larly PECAM-1-stained microvessels were noted in
carcinoma tumor sections (Figure 3a). The PECAM-1
antibody did not stain microvessels in melanoma
tumors, and isolectin GSL1-B4 stained Lewis lung
carcinoma cells (data not shown). At high magnification
we observed that the microvessel density in melanoma
tumors in CIB1-KO mice was 29% less than that
observed in tumors isolated from WT mice (p = 0.002;
Figure 3b). Correspondingly, the microvessel density in
carcinoma tumors in CIB1-KO mice trended lower,
although this potential difference did not reach a
p value < 0.05 (26% decrease, p = 0.08; Figure 3c).
Therefore, these data demonstrate that not only do allo-
grafted melanoma tumors in CIB1-KO mice have
increased incidence of necrosis, but they also have
reduced intra-tumoral neovascularization.
The decreased microvessel density in allografted
tumors in CIB1-KO mice may be due to decreased
expression and secretion of MMP-2 by CIB1-KO ECs,
which we reported previously [21]. Itoh et al. (1998)
demonstrated that MMP-2-KO mice have decreased
tumor growth and metastasis. In accordance with our
observations, the study also reported that MMP-2-KO
mice have significantly decreased B16 melanoma and
Lewis lung carcinoma allograft tumor growth. Since this
decrease in tumor growth was largely unaffected by the
difference in expression of MMP-2 by melanoma and
carcinoma cells, the authors concluded that host-derived
MMP-2 has a critical role in tumor progression and
angiogenesis. Likewise, melanoma tumors in CIB1-KO
mice have significantly decreased tumor-derived and
host-derived MMP-2. Minimal MMP-2 would at least in
part explain the decrease observed in allograft tumor
growth and neovascularization in CIB1-KO mice. In
addition, it would also suggest an alternative explanation
for why a higher incidence of gross and histological
necrosis was noted in melanomas, but not in carcinomas
Figure 1 Allograft tumors in CIB1-KO mice are smaller and
have a distinct morphological appearance. (a) Two
representative images of B16 melanoma tumors or Lewis lung
carcinoma tumors that developed after 14 days in either WT or
CIB1-KO mice. Tumors in CIB1-KO mice had a distinct morphological
appearance, with gross necrosis of melanoma tumors and blanching
of carcinoma tumors. (b, c) Tumors that developed in CIB1-KO mice
were smaller in volume and weight compared to WT mice, but no
significant difference was noted for melanoma tumor weight. Error
bars are ± SEM (n = 8-11 mice per group; * p < 0.05).
Table 1 Melanoma tumors have more gross necrosis in
CIB1-KO mice
Mouse
Genotype
Total
Number
of Mice
Mice with
Tumor
Necrosis
Mice with
No Tumor
Necrosis
% of Mice
with Tumor
Necrosis
B16
Melanoma
Tumorsa
WT 9 3 6 33.3%
CIB1-KO 11 7 4 63.6%b
Lewis Lung
Carcinoma
Tumors
WT 8 0 8 0.0%
CIB1-KO 9 0 9 0.0%c
aTumor necrosis was grossly evident in B16 melanoma tumors that developed
in both WT and CIB1-KO mice.
bThe number of tumors with clear evidence of gross necrosis in CIB1-KO mice
was statistically significant (p = 0.05), chi-square test with one degree of
freedom.
cThere was no evidence of gross necrosis in Lewis lung carcinoma tumors that
developed in both WT and CIB1-KO mice.
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that have high levels of tumor-derived MMP-2 and low
levels of host-derived MMP2.
The combination of increased tumor necrosis and
decreased tumor-induced angiogenesis in CIB1-KO mice
may also be a direct result of attenuated EC signaling in
these mice. As previously reported, ECs deficient in CIB1
have reduced PAK1 activation. The activation of this ser-
ine/threonine kinase is an important point of conver-
gence between growth factor- and integrin-induced
signaling that is mediated by small GTP-bound GTPases
such as Cdc42 [30,31]. Leisner et al. demonstrated that
CIB1 binds to PAK1, thus preventing its interaction with
Cdc42 and subsequent activation in various cell types
[16]. Since PAK1 primarily mediates its effects on ECs
via the Ras-Raf-ERK1/2 MAPK signaling pathway [18],
we previously tested whether MAPK signaling is affected
when CIB1 is not present. ERK1/2, but not p38, MAPK
signaling was significantly attenuated in CIB1-KO ECs
in vitro, and in CIB1-KO ischemic and non-ischemic
muscles in vivo [21]. Thus, a CIB1-mediated inhibition of
the PAK1-ERK1/2 pathway may explain the decrease
noted in tumor-induced angiogenesis in CIB1-KO mice.
Figure 2 Increased microscopic necrosis and bleeding in CIB1-KO allograft tumors. Fourteen days after tumor cell injection, tumors were
isolated from animals and fixed. Sections were sectioned and stained with H&E or Masson’s trichrome (MT) as described in Methods.
Representative images were captured at two different magnifications using a Nikon D100 camera attached to a Nikon inverted microscope.
Representative low magnification images (a, d, g, and j), and high magnification (b, c, e, f, h, i, k, and l) of melanoma and carcinoma tumors.
Areas of necrosis (N) and bleeding are noted on H&E-stained sections (a, b, d, e, g, h, j, and k). Fibrosis stained in blue (identified with yellow
arrows) is noted on MT-stained sections (c, f, i, and l).
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Further studies are currently underway to determine if
PAK1 downstream targets such as MMP-9 and TIMP-1
are also affected by levels of CIB1 expression.
There may also be alternative mechanisms by which
CIB1 mediates its effects on tumor growth and neovas-
cularization. We have observed decreased monolayer
resistance in CIB1-KO ECs (unpublished data), suggest-
ing that CIB1 is necessary for proper EC monolayer per-
meability in vitro. Related to this observation, in
preliminary analysis of gene array studies we found that
PECAM1 was among the most significantly downregu-
lated genes in CIB1-KO ECs (p = 0.017, unpublished
data). Not only is PECAM1 important for maintaining
EC monolayer integrity, but it also plays an essential
role in tumor growth and metastasis [32,33]. For exam-
ple, local administration of anti-murine antibodies tar-
geting EC-expressed PECAM1 inhibits both growth
factor- and tumor-induced angiogenesis in vivo [34].
Thus, like PECAM-KO mice (which are fertile and
viable; Duncan et al., 1999), CIB1-KO mice may also
have an underlying endothelial permeability defect that
does not manifest overtly, but affects pathological tumor
growth. Such defects in CIB1-KO ECs would play a
large part in the increased gross and microscopic allo-
graft tumor bleeding observed in our study. Further stu-
dies are currently underway to characterize the nature
of these defects and the implications they have on both
physiological and other pathological processes.
Figure 3 Melanoma in CIB1-KO mice have reduced vascularization. (a) Representative immunoflorescent images of Isolectin GSL1-B4-stained
melanoma tumor sections and PECAM-1-stained carcinoma tumor sections. The number of vessels with a clear lumen and < 7 μm in melanoma
(b) and carcinoma (c) tumors were counted by a blinded observer. Tumor microvessel density is reported as the average number of intra-
tumoral microvessels per frame. Error bars are ± SEM (n = 7 - 11 mice per group; * p < 0.05).
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Conclusions
Taken together, our findings support a model in which
CIB1 plays an important role in regulating tumor viabi-
lity, growth, and angiogenesis. We propose that CIB1
mediates these effects at least in part through its pre-
viously characterized role in PAK1-ERK1/2-MMP-2 sig-
naling. The fact that more necrosis and bleeding was
noted in melanoma tumors in CIB1-KO mice, where
there is a relative lack of MMP-2, suggests that this
mechanism may be a major pathway mediating the
observed effects in this study. Hence the data herein
establish a regulatory role for CIB1 in tumor growth
and pathological tumor-induced angiogenesis.
Additional material
Additional file 1: Carcinoma tumors in CIB1-KO mice have less areas
of high perfusion. Carcinoma tumors in CIB1-KO mice have reduced
perfusion. Superficial hind-limb ventral adductor thigh regions, where
tumor cells were injected, were monitored with noninvasive scanning
laser-Doppler perfusion imaging (model LD12-IR, Moor Instruments;
modified for high resolution and depth of penetration (2 mm) with an
830 nm-wavelenght infrared 2.5 mW laser diode, 100 μm beam diameter,
and 15 kHz bandwidth). Isofluorane anesthesia and rectal temperature
(37 ± 0.5°C) were maintained the same for all measurement days and
among animals. (a) Laser-Doppler perfusion imaging at the site of tumor
injection pre- (day 1), and day-7 and -14 after tumor cell injection. Image
scans are assembled from the mean Doppler velocity (in perfusion units,
PU) for each 100 × 2000 μm voxel in the scan area. (b) Regions of
interest (ROI) were drawn around tumor perimeters, to derive a tumor
area, and determine what percentage of the area had a detectable
Doppler signal. For every given ROI, a tumor perfusion index was
calculated using: (Average PU) × (ROI area) × (% ROI with detectable
Doppler signal)/10,000. Error bars are ± SEM (n = 8-9 mice per group).
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